The Neurological Institute of New York, is an American hospital research center located at 710 West 168th Street at the corner of Fort Washington Avenue in the NewYork-Presbyterian Hospital / Columbia University Medical Center in the Washington Heights neighborhood of Manhattan, New York City.

During the past decade, Columbia University Medical Center-The Neurological Institute of New York conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 9 clinical trials were completed, i.e. on average, 52.9% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 6 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Columbia University Medical Center-The Neurological Institute of New York" #1 sponsor was "Ionis Pharmaceuticals, Inc." with 4 trials, followed by "Cytokinetics" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Novartis Pharmaceuticals" with 2 trials sponsored and "Atara Biotherapeutics" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Columbia University Medical Center-The Neurological Institute of New York" #1 collaborator was "American Association of Neurological Surgeons" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator and "Orion Corporation, Orion Pharma" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Columbia University Medical Center-The Neurological Institute of New York" are "Amyotrophic Lateral Sclerosis" (4 trials), "Amyloidosis" (2 trials), "FAP" (2 trials), "Familial Amyloid Polyneuropathy" (2 trials) and "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy" (2 trials). Many other conditions were trialed in "Columbia University Medical Center-The Neurological Institute of New York" in a lesser frequency.

Most popular intervention types in "Columbia University Medical Center-The Neurological Institute of New York" are "Drug" (26 trials), "Biological" (3 trials), "Procedure" (3 trials), "Behavioral" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Inotersen" (3 trials), "Risdiplam" (3 trials), "Eplontersen" (2 trials) and "ATA188" (1 trials). Other intervention names were less common.

The vast majority of trials in "Columbia University Medical Center-The Neurological Institute of New York" are 29 trials for "All" genders.

Currently, there are NaN active trials in "Columbia University Medical Center-The Neurological Institute of New York". undefined are not yet recruiting, 2 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Columbia University Medical Center-The Neurological Institute of New York, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Columbia University Medical Center-The Neurological Institute of New York, 3 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".